CureVac propels cancer vaccine in $601m Boehringer Ingelheim deal

CureVac intends to harness the resources and cash of partners to advance its oncology vaccines, starting with a Boehringer Ingelheim deal worth up to €465m ($601m) in upfront and milestone payments.